Incidence and survival outcomes of myocarditis and pericardial diseases associated with immune checkpoint inhibitor therapy.

ABSTRACT:

Introduction

Immune checkpoint inhibitor(ICI) induced cardiac immune related adverse events are challenging to study; Leveraging large data bases like TriNetX global health network may provide needed insights.

Methods

We performed a retrospective cohort study including patients diagnosed neoplasm and 18 and older when receiving ICI therapy from 1/1/2011 to 12/31/2022. Queried ICD 9/10 codes identified patients experiencing myocarditis, pericarditis, pericardial effusion, and cardiac tamponade within 1 year of ICI initiation. Survival analyses compared one-year overall survival (OS) of patients experiencing cardiac irAEs against propensity score matched populations not experiencing them.

Results

In 88,928 identified ICI patients, the incidence of myocarditis(0.48%), pe

SUBMITTER: Ozaki AF 

PROVIDER: S-EPMC11881249 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature